chevron_leftBack
As of 13 June 2026, HilleVax, Inc. has a market cap of $104.79M USD, ranking #25207 globally and #3895 in the United States.
It ranks #2258 in the Healthcare sector, and #433 in the Biotechnology industry.
Key Stats
Market Cap
$104.79MUSD
EBITDA (TTM)
-$50.91MUSD
Net Income (TTM)
-$71.1MUSD
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Robert Hershberg
open_in_new
Employees
14
Founded
2020
IPO
29 Apr 2022
Website
hillevax.com
open_in_new
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 0% | -0.9% | 0.5% | 12% | 19% | 17% |
News
Loading...
HLVX Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
HLVX
HilleVax Inc
ISIN: US43157M1027
Shares Out.:
Shares Outstanding:
50.141M1
Shares Float:
22.743M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
2.09 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About HilleVax, Inc.
HilleVax, Inc., a clinical-stage biopharmaceutical company, develops and commercializes vaccines in the United States. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. It has a license agreement with Takeda Vaccines, Inc. to develop and commercialize HIL-214 pharmaceutical products. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
174K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
153K%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
26K%
|
-
|
|
NYSE: IQV
|
$26.3B
25K%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
24K%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
17K%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$47.84B
46K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.84B
43K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.36B
40K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.3B
40K%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$28.11B
27K%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
24K%
|
-
|
chevron_leftBack